Clinical Trial

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

Study acronym: NeoDREAM
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2018-06-22; most recent amendment 2025-12-15.
Status change: Not Yet Recruiting → Recruiting 2018-12-12
Trial Details
NCT Number NCT03567889
Lead Sponsor Philogen S.p.A.
Conditions Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
Enrollment 186 participants
Start Date 2018-09-20
Primary Completion 2027-12 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-17